Advanced search
Publication Cover
Personalized Medicine Volume 10, 2013 - Issue 4
Submit an article Journal homepage
1,016
Views
0
CrossRef citations to date
0
Altmetric
Review

Clinical Application of Targeted and Genome-Wide Technologies: Can we Predict Treatment Responses in Chronic Lymphocytic Leukemia?

Reem Alsolami1 Oxford National Institute for Health Research Biomedical Research Centre, University of Oxford, Oxford, UK;2 King Abdulaziz University, Faculty of Applied Medical Sciences, Jeddah, Saudi Arabia
,
Samantha JL Knight1 Oxford National Institute for Health Research Biomedical Research Centre, University of Oxford, Oxford, UK;3 Wellcome Trust Centre for Human Genetics, University of Oxford, Oxford, UK
&
Anna Schuh1 Oxford National Institute for Health Research Biomedical Research Centre, University of Oxford, Oxford, UKCorrespondence[email protected]
Pages 361-376 | Published online: 06 Jun 2013

References

  • Vardiman JW , HarrisNL, BrunningRD. The World Health Organization (WHO) classification of the myeloid neoplasms. Blood100(7) , 2292–2302 (2002).
  • Estey EH . Acute myeloid leukemia: 2012 update on diagnosis, risk stratification, and management. Am. J. Hematol.87(1) , 89–99 (2012).
  • Sullivan C , PengC, ChenY, LiD, LiS. Targeted therapy of chronic myeloid leukemia. Biochem. Pharmacol.80(5) , 584–591 (2010).
  • Tallman MS , BrennerB, Serna Jde L et al. Meeting report. Acute promyelocytic leukemia-associated coagulopathy, 21 January 2004, London, United Kingdom. Leuk. Res.29(3) , 347–351 (2005).
  • Howlader N , NooneA, KrapchoM et al. SEER Cancer Statistics Review 1975–2009 (Vintage 2009 Populations). National Cancer Institute, MD, USA (2012).
  • Zenz T , MertensD, KuppersR, DohnerH, StilgenbauerS. From pathogenesis to treatment of chronic lymphocytic leukaemia. Nat. Rev. Cancer10(1) , 37–50 (2010).
  • Clifford R , SchuhA. State-of-the-art management of patients suffering from chronic lymphocytic leukemia. Clin. Med. Insights Oncol.6 , 165–178 (2012).
  • Hallek M , FischerK, Fingerle-RowsonG et al. Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, Phase 3 trial. Lancet 376(9747) , 1164–1174 (2010).
  • Robak T , DmoszynskaA, Solal-CelignyP et al. Rituximab plus fludarabine and cyclophosphamide prolongs progression-free survival compared with fludarabine and cyclophosphamide alone in previously treated chronic lymphocytic leukemia. J. Clin. Oncol. 28(10) , 1756–1765 (2010).
  • Dohner H , StilgenbauerS, BennerA et al. Genomic aberrations and survival in chronic lymphocytic leukemia. N. Engl. J. Med. 343(26) , 1910–1916 (2000).
  • Dohner H , StilgenbauerS, FischerK, BentzM, LichterP. Cytogenetic and molecular cytogenetic analysis of B cell chronic lymphocytic leukemia: specific chromosome aberrations identify prognostic subgroups of patients and point to loci of candidate genes. Leukemia11(Suppl. 2) , S19–S24 (1997).
  • Klein U , LiaM, CrespoM et al. The DLEU2/miR-15a/16–1 cluster controls B cell proliferation and its deletion leads to chronic lymphocytic leukemia. Cancer Cell 17(1) , 28–40 (2010).
  • Zenz T , EichhorstB, BuschR et al. TP53 mutation and survival in chronic lymphocytic leukemia. J. Clin. Oncol.28(29) , 4473–4479 (2010).
  • Stankovic T , KiddAM, SutcliffeA et al. ATM mutations and phenotypes in ataxia-telangiectasia families in the British Isles: expression of mutant ATM and the risk of leukemia, lymphoma, and breast cancer. Am. J. Hum. Genet. 62(2) , 334–345 (1998).
  • Puente XS , PinyolM, QuesadaV et al. Whole-genome sequencing identifies recurrent mutations in chronic lymphocytic leukaemia. Nature 475(7354) , 101–105 (2011).
  • Schuh A , BecqJ, HumphrayS et al. Monitoring chronic lymphocytic leukemia progression by whole genome sequencing reveals heterogeneous clonal evolution patterns. Blood 120(20) , 4191–4196 (2012).
  • Cramer P , HallekM. Prognostic factors in chronic lymphocytic leukemia – what do we need to know? Nat. Rev. Clin. Oncol.8(1) , 38–47 (2011).
  • Oldenhuis CN , OostingSF, GietemaJA, de Vries EG. Prognostic versus predictive value of biomarkers in oncology. Eur. J. Cancer44(7) , 946–953 (2008).
  • Zenz T , FrohlingS, MertensD, DohnerH, StilgenbauerS. Moving from prognostic to predictive factors in chronic lymphocytic leukaemia (CLL). Best Pract. Res. Clin. Haematol.23(1) , 71–84 (2010).
  • Malek SN . The biology and clinical significance of acquired genomic copy number aberrations and recurrent gene mutations in chronic lymphocytic leukemia. Oncogene doi:10.1038/onc.2012.411 (2012) (Epub ahead of print).
  • Hillmen P . Using the biology of chronic lymphocytic leukemia to choose treatment. Hematology Am. Soc. Hematol. Educ. Program2011 , 104–109 (2011).
  • Moreno C , MontserratE. New prognostic markers in chronic lymphocytic leukemia. Blood Rev.22(4) , 211–219 (2008).
  • Dohner H , FischerK, BentzM et al. p53 gene deletion predicts for poor survival and non-response to therapy with purine analogs in chronic B-cell leukemias. Blood 85(6) , 1580–1589 (1995).
  • Catovsky D , RichardsS, MatutesE et al. Assessment of fludarabine plus cyclophosphamide for patients with chronic lymphocytic leukaemia (the LRF CLL4 trial): a randomised controlled trial. Lancet 370(9583) , 230–239 (2007).
  • Grever MR , LucasDM, DewaldGW et al. Comprehensive assessment of genetic and molecular features predicting outcome in patients with chronic lymphocytic leukemia: results from the US Intergroup Phase III trial E2997. J. Clin. Oncol. 25(7) , 799–804 (2007).
  • Saddler C , OuilletteP, KujawskiL et al. Comprehensive biomarker and genomic analysis identifies p53 status as the major determinant of response to MDM2 inhibitors in chronic lymphocytic leukemia. Blood 111(3) , 1584–1593 (2008).
  • Malcikova J , SmardovaJ, RocnovaL et al. Monoallelic and biallelic inactivation of TP53 gene in chronic lymphocytic leukemia: selection, impact on survival, and response to DNA damage. Blood 114(26) , 5307–5314 (2009).
  • Zenz T , HabeS, DenzelT et al. Detailed analysis of p53 pathway defects in fludarabine-refractory chronic lymphocytic leukemia (CLL): dissecting the contribution of 17p deletion, TP53 mutation, p53-p21 dysfunction, and miR34a in a prospective clinical trial. Blood 114(13) , 2589–2597 (2009).
  • Rossi D , CerriM, DeambrogiC et al. The prognostic value of TP53 mutations in chronic lymphocytic leukemia is independent of Del17p13: implications for overall survival and chemorefractoriness. Clin. Cancer Res. 15(3) , 995–1004 (2009).
  • Oscier D , WadeR, DavisZ et al. Prognostic factors identified three risk groups in the LRF CLL4 trial, independent of treatment allocation. Haematologica 95(10) , 1705–1712 (2010).
  • Ouillette P , CollinsR, ShakhanS et al. Acquired genomic copy number aberrations and survival in chronic lymphocytic leukemia. Blood 118(11) , 3051–3061 (2011).
  • Gonzalez D , MartinezP, WadeR et al. Mutational status of the TP53 gene as a predictor of response and survival in patients with chronic lymphocytic leukemia: results from the LRF CLL4 trial. J. Clin. Oncol. 29(16) , 2223–2229 (2011).
  • Pospisilova S , GonzalezD, MalcikovaJ et al. ERIC recommendations on TP53 mutation analysis in chronic lymphocytic leukemia. Leukemia 26(7) , 1458–1461 (2012).
  • Oscier D , DeardenC, EremE et al. Guidelines on the diagnosis, investigation and management of chronic lymphocytic leukaemia. Br. J. Haematol. 159(5) , 541–564 (2012).
  • Skowronska A , ParkerA, AhmedG et al. Biallelic ATM inactivation significantly reduces survival in patients treated on the United Kingdom Leukemia Research Fund Chronic Lymphocytic Leukemia 4 trial. J. Clin. Oncol. 30(36) , 4524–4532 (2012).
  • Tsimberidou AM , TamC, AbruzzoLV et al. Chemoimmunotherapy may overcome the adverse prognostic significance of 11q deletion in previously untreated patients with chronic lymphocytic leukemia. Cancer 115(2) , 373–380 (2009).
  • Dewald GW , BrockmanSR, PaternosterSF et al. Chromosome anomalies detected by interphase fluorescence in situ hybridization: correlation with significant biological features of B-cell chronic lymphocytic leukaemia. Br. J. Haematol. 121(2) , 287–295 (2003).
  • Shanafelt TD , WitzigTE, FinkSR et al. Prospective evaluation of clonal evolution during long-term follow-up of patients with untreated early-stage chronic lymphocytic leukemia. J. Clin. Oncol. 24(28) , 4634–4641 (2006).
  • Oscier DG , GardinerAC, MouldSJ et al. Multivariate analysis of prognostic factors in CLL: clinical stage, IGVH gene mutational status, and loss or mutation of the p53 gene are independent prognostic factors. Blood 100(4) , 1177–1184 (2002).
  • Zenz T , KroberA, SchererK et al. Monoallelic TP53 inactivation is associated with poor prognosis in chronic lymphocytic leukemia: results from a detailed genetic characterization with long-term follow-up. Blood 112(8) , 3322–3329 (2008).
  • Stilgenbauer S , ZenzT, WinklerD et al. Subcutaneous alemtuzumab in fludarabine-refractory chronic lymphocytic leukemia: clinical results and prognostic marker analyses from the CLL2H study of the German Chronic Lymphocytic Leukemia Study Group. J. Clin. Oncol. 27(24) , 3994–4001 (2009).
  • Pettitt AR , JacksonR, CarruthersS et al. Alemtuzumab in combination with methylprednisolone is a highly effective induction regimen for patients with chronic lymphocytic leukemia and deletion of TP53 : final results of the national cancer research institute CLL206 trial. J. Clin. Oncol. 30(14) , 1647–1655 (2012).
  • Khaja R , ZhangJ, MacdonaldJR et al. Genome assembly comparison identifies structural variants in the human genome. Nat. Genet. 38(12) , 1413–1418 (2006).
  • Redon R , IshikawaS, FitchKR et al. Global variation in copy number in the human genome. Nature 444(7118) , 444–454 (2006).
  • Beroukhim R , MermelCH, PorterD et al. The landscape of somatic copy-number alteration across human cancers. Nature 463(7283) , 899–905 (2010).
  • Knight SJ , YauC, CliffordR et al. Quantification of subclonal distributions of recurrent genomic aberrations in paired pre-treatment and relapse samples from patients with B-cell chronic lymphocytic leukemia. Leukemia 26(7) , 1564–1575 (2012).
  • Edelmann J , HolzmannK, MillerF et al. High-resolution genomic profiling of chronic lymphocytic leukemia reveals new recurrent genomic alterations. Blood 120(24) , 4783–4794 (2012).
  • Hagenkord JM , MonzonFA, KashSF, LillebergS, XieQ, KantJA. Array-based karyotyping for prognostic assessment in chronic lymphocytic leukemia: performance comparison of Affymetrix 10.2.0, 250K Nsp, and SNP6.0 arrays. J. Mol. Diagn.12(2) , 184–196 (2010).
  • Lehmann S , OgawaS, RaynaudSD et al. Molecular allelokaryotyping of early-stage, untreated chronic lymphocytic leukemia. Cancer 112(6) , 1296–1305 (2008).
  • Zenz T , BennerA, DohnerH, StilgenbauerS. Chronic lymphocytic leukemia and treatment resistance in cancer: the role of the p53 pathway. Cell Cycle7(24) , 3810–3814 (2008).
  • Gunnarsson R , StaafJ, JanssonM et al. Screening for copy-number alterations and loss of heterozygosity in chronic lymphocytic leukemia – a comparative study of four differently designed, high resolution microarray platforms. Genes Chromosomes Cancer 47(8) , 697–711 (2008).
  • Conlin LK , ThielBD, BonnemannCG et al. Mechanisms of mosaicism, chimerism and uniparental disomy identified by single nucleotide polymorphism array analysis. Hum. Mol. Genet. 19(7) , 1263–1275 (2010).
  • Tuna M , KnuutilaS, MillsGB. Uniparental disomy in cancer. Trends Mol. Med.15(3) , 120–128 (2009).
  • Tan DS , LambrosMB, NatrajanR, Reis-FilhoJS. Getting it right: designing microarray (and not ‘microawry‘) comparative genomic hybridization studies for cancer research. Lab. Invest.87(8) , 737–754 (2007).
  • Barrett MT , SchefferA, Ben-DorA et al. Comparative genomic hybridization using oligonucleotide microarrays and total genomic DNA. Proc. Natl Acad. Sci. USA 101(51) , 17765–17770 (2004).
  • Zhang L , ZnoykoI, CostaLJ et al. Clonal diversity analysis using SNP microarray: a new prognostic tool for chronic lymphocytic leukemia. Cancer Genet. 204(12) , 654–665 (2011).
  • Miecznikowski JC , GaileDP, LiuS, ShepherdL, NowakN. A new normalizing algorithm for BAC CGH arrays with quality control metrics. J. Biomed. Biotechnol.2011 , 860732 (2011).
  • Alkan C , CoeBP, EichlerEE. Genome structural variation discovery and genotyping. Nat. Rev. Genet.12(5) , 363–376 (2011).
  • Gunderson KL , SteemersFJ, LeeG, MendozaLG, CheeMS. A genome-wide scalable SNP genotyping assay using microarray technology. Nat. Genet.37(5) , 549–554 (2005).
  • Oliphant A , BarkerDL, StuelpnagelJR, CheeMS. BeadArray technology: enabling an accurate, cost–effective approach to high-throughput genotyping. BioTechniques (Suppl. 56–58) , 60–51 (2002).
  • Biesecker LG , SpinnerNB. A genomic view of mosaicism and human disease. Nat. Rev. Genet.14(5) , 307–320 (2013).
  • Gonzalez JR , Rodriguez-SantiagoB, CaceresA et al. A fast and accurate method to detect allelic genomic imbalances underlying mosaic rearrangements using SNP array data. BMC Bioinformatics 12 , 166 (2011).
  • Markello TC , Carlson-DonohoeH, SincanM et al. Sensitive quantification of mosaicism using high density SNP arrays and the cumulative distribution function. Mol. Genet. Metab. 105(4) , 665–671 (2012).
  • Bruno DL , StarkZ, AmorDJ et al. Extending the scope of diagnostic chromosome analysis: detection of single gene defects using high-resolution SNP microarrays. Hum. Mutat. 32(12) , 1500–1506 (2011).
  • Grubor V , KrasnitzA, TrogeJE et al. Novel genomic alterations and clonal evolution in chronic lymphocytic leukemia revealed by representational oligonucleotide microarray analysis (ROMA). Blood 113(6) , 1294–1303 (2009).
  • Gunn SR , BollaAR, BarronLL et al. Array CGH analysis of chronic lymphocytic leukemia reveals frequent cryptic monoallelic and biallelic deletions of chromosome 22q11 that include the PRAME gene. Leuk. Res. 33(9) , 1276–1281 (2009).
  • Rodriguez AE , RobledoC, GarciaJL et al. Identification of a novel recurrent gain on 20q13 in chronic lymphocytic leukemia by array CGH and gene expression profiling. Ann. Oncol. 23(8) , 2138–2146 (2012).
  • Sellick GS , WadeR, RichardsS, OscierDG, CatovskyD, HoulstonRS. Scan of 977 nonsynonymous SNPs in CLL4 trial patients for the identification of genetic variants influencing prognosis. Blood111(3) , 1625–1633 (2008).
  • Pfeifer D , PanticM, SkatullaI et al. Genome-wide analysis of DNA copy number changes and LOH in CLL using high-density SNP arrays. Blood 109(3) , 1202–1210 (2007).
  • Gunn SR , MohammedMS, GorreME et al. Whole-genome scanning by array comparative genomic hybridization as a clinical tool for risk assessment in chronic lymphocytic leukemia. J. Mol. Diagn. 10(5) , 442–451 (2008).
  • Kay NE , Eckel-PassowJE, BraggioE et al. Progressive but previously untreated CLL patients with greater array CGH complexity exhibit a less durable response to chemoimmunotherapy. Cancer Genet. Cytogenet. 203(2) , 161–168 (2010).
  • Van Den Neste E , RobinV, FrancartJ et al. Chromosomal translocations independently predict treatment failure, treatment-free survival and overall survival in B-cell chronic lymphocytic leukemia patients treated with cladribine. Leukemia 21(8) , 1715–1722 (2007).
  • Gunnarsson R , MansouriL, IsakssonA et al. Array-based genomic screening at diagnosis and during follow-up in chronic lymphocytic leukemia. Haematologica 96(8) , 1161–1169 (2011).
  • Braggio E , KayNE, VanwierS et al. Longitudinal genome-wide analysis of patients with chronic lymphocytic leukemia reveals complex evolution of clonal architecture at disease progression and at the time of relapse. Leukemia 26(7) , 1698–1701 (2012).
  • Mian M , RinaldiA, MensahAA et al. Large genomic aberrations detected by SNP array are independent prognosticators of a shorter time to first treatment in chronic lymphocytic leukemia patients with normal FISH. Ann. Oncol. 24(5) , 1378–1384 (2013).
  • O‘Malley DP , GiudiceC, ChangAS et al. Comparison of array comparative genomic hybridization (aCGH) to FISH and cytogenetics in prognostic evaluation of chronic lymphocytic leukemia. Int. J. Lab. Hematol. 33(3) , 238–244 (2011).
  • Gunn SR , HibbardMK, IsmailSH et al. Atypical 11q deletions identified by array CGH may be missed by FISH panels for prognostic markers in chronic lymphocytic leukemia. Leukemia 23(5) , 1011–1017 (2009).
  • Hagenkord JM , MonzonFA, KashSF, LillebergS, XieQ, KantJA. Array-based karyotyping for prognostic assessment in chronic lymphocytic leukemia: performance comparison of affymetrix 10.2.0, 250K Nsp, and SNP6.0 arrays. J. Mol. Diagn.12(2) , 184–196 (2010).
  • Sherry ST , WardMH, KholodovM et al. dbSNP: the NCBI database of genetic variation. Nucleic Acids Res. 29(1) , 308–311 (2001).
  • International Hapmap C. The International HapMap Project. Nature426(6968) , 789–796 (2003).
  • Iafrate AJ , FeukL, RiveraMN et al. Detection of large-scale variation in the human genome. Nat. Genet. 36(9) , 949–951 (2004).
  • Lappalainen I , LopezJ, SkipperL et al. DbVar and DGVa: public archives for genomic structural variation. Nucleic Acids Res. 41(Database issue) , D936–D941 (2013).
  • Metzker ML . Sequencing technologies – the next generation. Nat. Rev. Genet.11(1) , 31–46 (2010).
  • Gargis AS , KalmanL, BerryMW et al. Assuring the quality of next-generation sequencing in clinical laboratory practice. Nat. Biotechnol. 30(11) , 1033–1036 (2012).
  • Clark MJ , ChenR, LamHY et al. Performance comparison of exome DNA sequencing technologies. Nat. Biotechnol. 29(10) , 908–914 (2011).
  • Bamshad MJ , NgSB, BighamAW et al. Exome sequencing as a tool for Mendelian disease gene discovery. Nat. Rev. Genet. 12(11) , 745–755 (2011).
  • Gibson G . Rare and common variants: twenty arguments. Nat. Rev. Genet.13(2) , 135–145 (2011).
  • Ansorge WJ . Next-generation DNA sequencing techniques. New Biotechnol.25(4) , 195–203 (2009).
  • Fabbri G , RasiS, RossiD et al. Analysis of the chronic lymphocytic leukemia coding genome: role of NOTCH1 mutational activation. J. Exp. Med. 208(7) , 1389–1401 (2011).
  • Wang L , LawrenceMS, WanY et al. SF3B1 and other novel cancer genes in chronic lymphocytic leukemia. N. Engl. J. Med.365(26) , 2497–2506 (2011).
  • Mansouri L , CahillN, GunnarssonR et al. NOTCH1 and SF3B1 mutations can be added to the hierarchical prognostic classification in chronic lymphocytic leukemia. Leukemia27(2) , 512–514 (2013).
  • Landau DA , CarterSL, StojanovP et al. Evolution and impact of subclonal mutations in chronic lymphocytic leukemia. Cell 152(4) , 714–726 (2013).
  • Ellisen LW , BirdJ, WestDC et al. TAN-1, the human homolog of the Drosophila notch gene, is broken by chromosomal translocations in T lymphoblastic neoplasms. Cell 66(4) , 649–661 (1991).
  • Rossi D , RasiS, FabbriG et al. Mutations of NOTCH1 are an independent predictor of survival in chronic lymphocytic leukemia. Blood 119(2) , 521–529 (2012).
  • Rossi D , RasiS, SpinaV et al. Integrated mutational and cytogenetic analysis identifies new prognostic subgroups in chronic lymphocytic leukemia. Blood 121(8) , 1403–1412 (2013).
  • Lopez C , DelgadoJ, CostaD et al. Different distribution of NOTCH1 mutations in chronic lymphocytic leukemia with isolated trisomy 12 or associated with other chromosomal alterations. Genes Chromosomes Cancer 51(9) , 881–889 (2012).
  • Quesada V , CondeL, VillamorN et al. Exome sequencing identifies recurrent mutations of the splicing factor SF3B1 gene in chronic lymphocytic leukemia. Nat. Genet. 44(1) , 47–52 (2012).
  • Rosati E , SabatiniR, RampinoG et al. Constitutively activated Notch signaling is involved in survival and apoptosis resistance of B-CLL cells. Blood 113(4) , 856–865 (2009).
  • Fatima K , ParachaRZ, QadriI. Post-transcriptional silencing of Notch2 mRNA in chronic lymphocytic [corrected] leukemic cells of B-CLL patients. Mol. Biol. Rep.39(5) , 5059–5067 (2012).
  • Oscier DG , Rose-ZerilliMJ, WinkelmannN et al. The clinical significance of NOTCH1 and SF3B1 mutations in the UK LRF CLL4 trial. Blood 121(3) , 468–475 (2013).
  • Villamor N , CondeL, Martinez-TrillosA et al. NOTCH1 mutations identify a genetic subgroup of chronic lymphocytic leukemia patients with high risk of transformation and poor outcome. Leukemia27(5) , 1100–1106 (2013).
  • Fabbri M , UraniC, SaccoMG, ProcacciantiC, GribaldoL. Whole genome analysis and microRNAs regulation in HepG2 cells exposed to cadmium. Altex29(2) , 173–182 (2012).
  • Sportoletti P , BaldoniS, CavalliL et al. NOTCH1 PEST domain mutation is an adverse prognostic factor in B-CLL. Br. J. Haematol.151(4) , 404–406 (2010).
  • Shedden K , LiY, OuilletteP, MalekSN. Characteristics of chronic lymphocytic leukemia with somatically acquired mutations in NOTCH1 exon 34. Leukemia26(5) , 1108–1110 (2012).
  • Del Giudice I , RossiD, ChiarettiS et al. NOTCH1 mutations in +12 chronic lymphocytic leukemia (CLL) confer an unfavorable prognosis, induce a distinctive transcriptional profiling and refine the intermediate prognosis of +12 CLL. Haematologica97(3) , 437–441 (2012).
  • Stilgenbauer S BR, Andrea Schnaiter, Paschka P et al. Gene mutations and treatment outcome in chronic lymphocytic leukemia: results from the CLL8 trial. 53rd Annual Meeting and Exposition of the American Society of Hematology . Atlanta, GA, USA 10–13 December 2013.
  • Rosati E , SabatiniR, De Falco F et al. gamma-Secretase inhibitor I induces apoptosis in chronic lymphocytic leukemia cells by proteasome inhibition, endoplasmic reticulum stress increase and notch down-regulation. Int. J. Cancer132(8) , 1940–1953 (2013).
  • Visconte V , MakishimaH, JankowskaA et al. SF3B1, a splicing factor is frequently mutated in refractory anemia with ring sideroblasts. Leukemia26(3) , 542–545 (2012).
  • Schwaederle M , GhiaE, RassentiLZ et al. Subclonal evolution involving SF3B1 mutations in chronic lymphocytic leukemia. Leukemia 27(5) , 1214–1217 (2013).
  • Papaemmanuil E , CazzolaM, BoultwoodJ et al. Somatic SF3B1 mutation in myelodysplasia with ring sideroblasts. N. Engl. J. Med. 365(15) , 1384–1395 (2011).
  • Rossi D , FangazioM, RasiS et al. Disruption of BIRC3 associates with fludarabine chemorefractoriness in TP53 wild-type chronic lymphocytic leukemia. Blood 119(12) , 2854–2862 (2012).
  • Zenz T , GribbenJG, HallekM, DohnerH, KeatingMJ, StilgenbauerS. Risk categories and refractory CLL in the era of chemoimmunotherapy. Blood119(18) , 4101–4107 (2012).
  • Stilgenbauer S , LiebischP, JamesMR et al. Molecular cytogenetic delineation of a novel critical genomic region in chromosome bands 11q22.3–923.1 in lymphoproliferative disorders. Proc. Natl Acad. Sci. USA 93(21) , 11837–11841 (1996).
  • Kanduri M , TobinG, AleskogA, NilssonK, RosenquistR. The novel NF-kappaB inhibitor IMD-0354 induces apoptosis in chronic lymphocytic leukemia. Blood Cancer J.1(3) , e12 (2011).
  • Hertlein E , WagnerAJ, JonesJ et al. 17-DMAG targets the nuclear factor-kappaB family of proteins to induce apoptosis in chronic lymphocytic leukemia: clinical implications of HSP90 inhibition. Blood 116(1) , 45–53 (2010).
  • Ding L , LeyTJ, LarsonDE et al. Clonal evolution in relapsed acute myeloid leukaemia revealed by whole-genome sequencing. Nature 481(7382) , 506–510 (2012).
  • Keats JJ , ChesiM, EganJB et al. Clonal competition with alternating dominance in multiple myeloma. Blood 120(5) , 1067–1076 (2012).
  • Walter MJ , ShenD, DingL et al. Clonal architecture of secondary acute myeloid leukemia. N. Engl. J. Med. 366(12) , 1090–1098 (2012).
  • Mamanova L , CoffeyAJ, ScottCE et al. Target-enrichment strategies for next-generation sequencing. Nat. Methods 7(2) , 111–118 (2010).
  • Domenech E , Gomez-LopezG, Gzlez-PenaD et al. New mutations in chronic lymphocytic leukemia identified by target enrichment and deep sequencing. PloS ONE 7(6) , e38158 (2012).
  • Woyach JA , JohnsonAJ, ByrdJC. The B-cell receptor signaling pathway as a therapeutic target in CLL. Blood120(6) , 1175–1184 (2012).

▪ Websites

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.